Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

Table 1 Patient characteristics by BRCA-like ^CGH status

Variable	Patients with non-BRCA-like^CGHtumors		Patients with BRCA-like^CGHtumors		P values
	n	%	n	%
Total	168	67.5	81	32.5
Treatment
FE₉₀C chemotherapy	81	48.2	41	50.6	0.787
HD-CTC chemotherapy	87	51.8	40	49.4
Type of surgery
Breast-conserving therapy	33	19.6	18	22.2	0.620
Mastectomy	135	80.4	63	77.8	0.620
Age in categories
<40 years	34	20.2	27	33.3	0.032^*
40 - 49 years	91	54.2	39	48.1
≥50 years	43	25.6	15	18.5
Tumor classification
T1	32	19.0	15	18.5	0.642^*
T2	112	66.7	51	63.0
T3	23	13.7	14	17.3
Unknown	1	0.6	1	1.2
Number of positive lymph nodes
4-9	109	64.9	54	66.7	0.887
≥10	59	35.1	27	33.3	0.887
Histologic grade
I	51	30.4	4	4.9	<0.001^*
II	70	41.7	23	28.4
III	42	25.0	50	61.7
Not determined	5	3.0	4	4.9
Estrogen receptor status
Negative (<10%)	25	14.9	40	49.4	<0.001
Positive (≥10%)	143	85.1	41	50.6	<0.001
Progesterone receptor status
Negative (<10%)	50	29.8	51	63.0	<0.001
Positive (≥10%)	118	70.2	28	34.6
Unknown	0	0.0	2	2.5
Triple-negative status
Triple-negative	22	13.1	38	46.9	<0.001
ER or PR positive (>10%)	146	86.9	41	50.6
Unknown	0	0.0	2	2.5
P53 status
<10%	99	58.9	43	53.1	0.087^*
10 - 50%	48	28.6	11	13.6
>50%	16	9.5	19	23.5
Unknown	5	3.0	8	9.9

P values: patients with unknown values were omitted. P values were calculated using the Fisher’s exact test, except for *chi-square test for trend. FE₉₀C, 5-fluorouracil-epirubicin-cyclophosphamide; HD-CTC, high-dose cyclophosphamide-thiotepa-carboplatin; ER, estrogen receptor; PR, progesterone receptor.

ISSN: 1465-542X